title: MK-0518 and GS-9137: two promising integrase inhibitors in the pipeline.
abstract: Possibly the most exciting news to come out of the 13th Conference on Retroviruses and Opportunistic Infections, held in Denver last February, concerned clinical trials of two experimental drugs in a new class: integrase inhibitors. If successful in further trials, integrase inhibitors could revitalize the treatment regimens of people living with multidrug-resistant HIV.
authors.forename: Reilly
authors.initials: R
authors.lastname: O'Neal
mesh_terms: D024882:Drug Resistance, Viral; D019428:HIV Integrase Inhibitors / Q000627:therapeutic use*; D009930:Organic Chemicals / Q000627:therapeutic use*; D011760:Pyrrolidinones; D015363:Quinolones / Q000627:therapeutic use*; D000068898:Raltegravir Potassium; D019562:Viral Load
chemical_list: D019428:HIV Integrase Inhibitors; D009930:Organic Chemicals; D011760:Pyrrolidinones; D015363:Quinolones; D000068898:Raltegravir Potassium; C509700:elvitegravir